290 related articles for article (PubMed ID: 16319514)
21. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
Ioka T; Ueno M; Ueno H; Park JO; Chang HM; Sasahira N; Kanai M; Chung IJ; Ikeda M; Nakamori S; Mizuno N; Omuro Y; Yamaguchi T; Hara H; Sugimori K; Furuse J; Maguchi H; Furukawa M; Fukuzawa K; Kim JS; Yukisawa S; Takeuchi M; Okusaka T; Boku N; Hyodo I
Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
[TBL] [Abstract][Full Text] [Related]
22. Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.
Cao C; Kuang M; Xu W; Zhang X; Chen J; Tang C
Jpn J Clin Oncol; 2015 Dec; 45(12):1122-30. PubMed ID: 26518328
[TBL] [Abstract][Full Text] [Related]
23. Phase I trial of oral S-1 plus gemcitabine in elderly patients with nonsmall cell lung cancer.
Kaira K; Sunaga N; Yanagitani N; Aoki H; Kawata T; Utsugi M; Shimizu Y; Shimizu K; Hisada T; Ishizuka T; Mori M
Anticancer Drugs; 2008 Mar; 19(3):289-94. PubMed ID: 18510175
[TBL] [Abstract][Full Text] [Related]
24. Phase I study of fixed dose rate infusion of gemcitabine in patients with unresectable pancreatic cancer.
Furuse J; Ishii H; Okusaka T; Nagase M; Nakachi K; Ueno H; Ikeda M; Morizane C; Yoshino M
Jpn J Clin Oncol; 2005 Dec; 35(12):733-8. PubMed ID: 16303793
[TBL] [Abstract][Full Text] [Related]
25. Biweekly gemcitabine plus S-1 for locally advanced and metastatic pancreatic cancer: a preliminary feasibility study.
Wada K; Sano K; Amano H; Miura F; Toyota N; Ito H; Shibuya M; Ikeda Y; Kainuma M; Takada T
J Hepatobiliary Pancreat Sci; 2015 Sep; 22(9):692-8. PubMed ID: 26136371
[TBL] [Abstract][Full Text] [Related]
26. A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer.
Nakachi K; Furuse J; Kinoshita T; Kawashima M; Ishii H; Ikeda M; Mitsunaga S; Shimizu S
Cancer Chemother Pharmacol; 2010 Aug; 66(3):527-34. PubMed ID: 19967537
[TBL] [Abstract][Full Text] [Related]
27. A phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer.
Uwagawa T; Misawa T; Sakamoto T; Ito R; Gocho T; Shiba H; Wakiyama S; Hirohara S; Sadaoka S; Yanaga K
Ann Oncol; 2009 Feb; 20(2):239-43. PubMed ID: 18836085
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of S-1 in combination with gemcitabine for chemo-naïve patients with locally advanced or metastatic pancreatic cancer.
Lee GW; Kim HJ; Ju JH; Kim SH; Kim HG; Kim TH; Kim HJ; Jeong CY; Kang JH
Cancer Chemother Pharmacol; 2009 Sep; 64(4):707-13. PubMed ID: 19151975
[TBL] [Abstract][Full Text] [Related]
29. Retrospective study of gemcitabine plus S-1 versus gemcitabine alone in cases with unresectable advanced pancreatic cancer.
Suzuki S; Ozaki Y; Saida S; Kaji S; Koike N; Harada N; Hayashi T; Suzuki M
Hepatogastroenterology; 2013 Jun; 60(124):916-20. PubMed ID: 23478143
[TBL] [Abstract][Full Text] [Related]
30. A Phase I Study of S-1 and Gemcitabine with Concurrent Radiotherapy in Patients with Non-Metastatic Advanced Pancreatic Cancer.
Kobayashi S; Honda G; Kurata M; Okuda Y; Sakamoto K; Karasawa K; Chang T; Egawa N; Kamisawa T; Omuro Y; Tsuruta K
Hepatogastroenterology; 2015 Jun; 62(140):1031-6. PubMed ID: 26902051
[TBL] [Abstract][Full Text] [Related]
31. Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer.
Kawashima H; Itoh A; Ohno E; Nakamura M; Miyahara R; Ohmiya N; Hara K; Kanamori A; Itoh T; Taki T; Hirai T; Hashimoto S; Takeda K; Goto H; Hirooka Y
Cancer Chemother Pharmacol; 2011 Sep; 68(3):677-83. PubMed ID: 21132496
[TBL] [Abstract][Full Text] [Related]
32. Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer.
Lee J; Park JO; Kim WS; Lee SI; Song SY; Lim DH; Choi SH; Heo JS; Lee KT; Lee JK; Kim K; Jung CW; Im YH; Lee MH; Kang WK; Park K
Oncology; 2004; 66(1):32-7. PubMed ID: 15031596
[TBL] [Abstract][Full Text] [Related]
33. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Ueno H; Ioka T; Ikeda M; Ohkawa S; Yanagimoto H; Boku N; Fukutomi A; Sugimori K; Baba H; Yamao K; Shimamura T; Sho M; Kitano M; Cheng AL; Mizumoto K; Chen JS; Furuse J; Funakoshi A; Hatori T; Yamaguchi T; Egawa S; Sato A; Ohashi Y; Okusaka T; Tanaka M
J Clin Oncol; 2013 May; 31(13):1640-8. PubMed ID: 23547081
[TBL] [Abstract][Full Text] [Related]
34. Clinical outcome of gemcitabine/S-1 combination therapy for advanced pancreatic cancer.
Yamauchi J; Kanai M; Matsumoto S; Nishimura T; Yazumi S; Kami K; Kawaguchi Y; Yasuda H; Kitano T; Misawa A; Ishiguro H; Yoshikawa K; Yanagihara K; Fukushima M; Doi R; Chiba T
Pancreas; 2008 Apr; 36(3):327-8. PubMed ID: 18362852
[No Abstract] [Full Text] [Related]
35. Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer.
Sudo K; Yamaguchi T; Nakamura K; Denda T; Hara T; Ishihara T; Yokosuka O
Cancer Chemother Pharmacol; 2011 Feb; 67(2):249-54. PubMed ID: 20352216
[TBL] [Abstract][Full Text] [Related]
36. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.
Morizane C; Okusaka T; Furuse J; Ishii H; Ueno H; Ikeda M; Nakachi K; Najima M; Ogura T; Suzuki E
Cancer Chemother Pharmacol; 2009 Jan; 63(2):313-9. PubMed ID: 18398614
[TBL] [Abstract][Full Text] [Related]
37. Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma.
Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Kondo N; Nakagawa N; Sueda T
J Surg Oncol; 2012 Aug; 106(2):174-80. PubMed ID: 22331838
[TBL] [Abstract][Full Text] [Related]
38. A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002).
Kanai M; Hatano E; Kobayashi S; Fujiwara Y; Marubashi S; Miyamoto A; Shiomi H; Kubo S; Ikuta S; Yanagimoto H; Terajima H; Ikoma H; Sakai D; Kodama Y; Seo S; Morita S; Ajiki T; Nagano H; Ioka T
Cancer Chemother Pharmacol; 2015 Feb; 75(2):293-300. PubMed ID: 25477010
[TBL] [Abstract][Full Text] [Related]
39. A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
Arima S; Shimizu K; Okamoto T; Toki M; Suzuki Y; Okano N; Naruge D; Kawai K; Kobayashi T; Kasuga A; Kitamura H; Takasu A; Nagashima F; Sugiyama M; Furuse J
Anticancer Res; 2017 Feb; 37(2):909-914. PubMed ID: 28179351
[TBL] [Abstract][Full Text] [Related]
40. A phase I/II study of fixed-dose-rate gemcitabine and S-1 with concurrent radiotherapy for locally advanced pancreatic cancer.
Goji T; Kimura T; Miyamoto H; Takehara M; Kagemoto K; Okada Y; Okazaki J; Takaoka Y; Miyamoto Y; Mitsui Y; Matsumoto S; Sueuchi T; Tanaka K; Fujino Y; Takaoka T; Kitamura S; Okamoto K; Kimura M; Sogabe M; Muguruma N; Okahisa T; Sato Y; Sagawa T; Fujikawa K; Sato Y; Ikushima H; Takayama T
Cancer Chemother Pharmacol; 2015 Sep; 76(3):615-20. PubMed ID: 26220846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
